327
Views
38
CrossRef citations to date
0
Altmetric
Research Article

Nanocarrier-based topical drug delivery for an antifungal drug

, , &
Pages 527-541 | Received 21 Nov 2012, Accepted 25 Jan 2013, Published online: 29 Apr 2013

References

  • Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–9
  • Gerbaud E, Tamion F, Girault C, et al. Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambosome). J Antimicrob Chemother 2003;51:473–5
  • Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis pf liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476--83
  • Osborne DW, Ward AJ, Neil KJ. Microemulsions as topical delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Phamacol 1991;43:450–4
  • Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv 1996;71:135–40
  • Azeem A, Rizwan M, Ahmad FJ, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSci Tech 2009;10:69
  • Porter CJ, Pouton CW. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008;60:625–37
  • Eccleston J. Microemulsions. In: Swarbrick J, Boylan JC, eds. Encyclopedia of pharmaceutical technology. Vol. 9. New York: Marcel Dekker; 1994:375–421
  • Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89–121
  • Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 1997;25:47–58
  • Khoo SM, Humberstone AJ, Porter CJH, et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998;167:155–64
  • Attwood D, Mallon D, Taylor CJ. Phase studies on oil in water microemulsions. Int J Pharm 1992;8:R5–8
  • Skalko N, Cajkovac M, Jalsˇenjak I. Liposomes with metronidazole for topical use: the choice of preparation method and vehicle. J Liposome Res 1998;8:283–93
  • Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Bio-phys Acta 1992;1107:271–82
  • OECD (The organization of Economic Co-operation Development), The OECD Guideline for testing of chemicals: 420 Acute Oral Toxicity. OECD, Paris. 2000;1e:14
  • Langevin D. Microemulsions. Acc Chem Res 1988;21:255–60
  • Ghosh PK, Murthy RS. Microemulsions: a potential drug delivery system. Curr Drug Deliv 2006;3:167–80
  • Krishnaiah YS, Satyanarayana V, Karthikeyan RS. Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Sci 2002;5:123–30
  • Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603–18
  • Tashtoush BM, Al-Safi SA, Al-Fanek KJ. Azathioprine transport through rat skin and its immunosuppressive effect. Pharmazie 2004;59:143–6
  • Reddy LH, Ghosh B. Enhancer aided in vitro permeation of atenolol and prazosin hydro-chloride through mice skin. Indian J Exp Biol 2001;39:47–51
  • Godwin DA, Michniak BB, Creek KE. Evaluation of transdermal penetration enhancers using a novel skin alternative. J Pharm Sci 1997;86:1001–5
  • Shin SC, Choi JS. Enhanced efficacy of triprolidine by transdermal application of the EVA matrix system in rabbits and rats. Eur J Pharm Biopharm 2005;61:14–19
  • Deray G. Amphotericin B nephrotoxicity. J. Antimicrob Chemother 2002;49:37–41
  • Falk R, Domb AJ, Polacheck I. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother 1999;43:1975–81
  • Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:2089–92
  • Maddux MS, Barriere AL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intel Clin Pharm 1980;14:177–81
  • Danaher PJ, Cao MK, Anstead GM, et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004;53:115–17

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.